The ABCB1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human hepatic adenocarcinoma cell line SK-HEP-1. This product features targeted disruption of the ABCB1 gene, encoding the multidrug efflux transporter P-glycoprotein (P-gp), creating a loss-of-function model to study drug disposition and resistance mechanisms without altering the endogenous hepatic background.
The SK-HEP-1 cell line, originally isolated from the ascitic fluid of a male patient with liver adenocarcinoma, serves as a well-established in vitro model for hepatic drug metabolism and hepatocellular carcinoma research. These cells exhibit an epithelial phenotype and are permissive for high-efficiency genome editing, providing a clinically relevant hepatic context to examine ABCB1-dependent drug efflux and its impact on chemotherapeutic efficacy.
ABCB1 encodes P-glycoprotein (P-gp), a membrane-bound ATP-binding cassette transporter that actively effluxes diverse xenobiotics and chemotherapeutic agents. Its transcription is controlled by nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR), and is further modulated by NF-??B, HIF-1??, p53, and Wnt/??-catenin signaling cascades. The transporter interacts with scaffolding proteins such as ezrin, radixin, moesin, and caveolin-1, which regulate its membrane localization and function. By reducing intracellular drug levels, P-gp suppresses apoptosis and engages downstream stress pathways, including JNK and p38 MAPK, ultimately fostering a multidrug-resistant phenotype.
In the hepatic adenocarcinoma SK-HEP-1 context, disruption of ABCB1 abolishes P-gp-mediated efflux, sensitizing cells to substrate anticancer drugs and enabling dissection of resistance mechanisms. This model is especially relevant for liver cancer research, where ABCB1 overexpression frequently correlates with therapy failure. Additionally, the hepatic background of SK-HEP-1 permits studies of drug-transporter interplay and liver-specific metabolic pathways, providing insights into the pharmacokinetic determinants of drug efficacy.
Key applications include high-throughput screening of P-gp inhibitors, functional transport assays using fluorescent substrates such as rhodamine 123 analyzed by flow cytometry, and cytotoxicity profiling of chemotherapeutics. The polyclonal knockout population better mirrors the genetic diversity of tumors compared to clonal isolates. Further uses encompass ATPase activity measurements, signaling pathway analyses, and pharmacokinetic modeling. For additional information or batch-specific characterization, please contact Ascent Research.
